Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. provides virtual primary care through a direct-to-patient telehealth platform that combines telemedicine, laboratory access, pharmacy services, a 50-state affiliated medical group, an affiliated pharmacy and a U.S.-based patient care center. Company news commonly covers its Telehealth operating segment, recurring subscription revenue, patient sign-ups, gross margin trends and guidance.
Recurring updates also address LifeMD’s specialized care areas, including primary care, men’s and women’s health, weight management and hormone therapy. News items feature GLP-1 weight management offerings such as Wegovy and Foundayo, branded therapy access through manufacturer programs, preferred stock dividends, executive leadership changes and investor conference participation.
LifeMD (Nasdaq: LFMD) reported full year 2025 revenue of $194.1 million (up 25%) and adjusted EBITDA of $15.3 million (up 309%). Q4 revenue was $46.9 million (+4%) with adjusted EBITDA of $4.8 million (+348%).
The company exited 2025 with $36.8 million cash, no debt, ~323,000 active subscribers, a benefits infrastructure to cover ~220 million Americans by Q2, and a post‑year‑end launch of oral Wegovy with >80% initiation among new weight management patients.
LifeMD (Nasdaq: LFMD) announced management will participate in two virtual investor conferences in March 2026.
Management will attend the Mizuho Securities Healthcare Technology Conference on March 5 with virtual one-on-one meetings, and the KeyBanc Capital Markets Healthcare Forum March 17-18 with a fireside chat and a panel on March 18.
LifeMD (Nasdaq: LFMD) will report fourth quarter and full-year 2025 financial results after market close on March 9, 2026 and will host a conference call and webcast at 4:30 p.m. Eastern the same day.
Dial-in numbers, conference ID LIFEMD, and a live/archived webcast link will be available for investors.
LifeMD (Nasdaq: LFMD) closed a new senior secured revolving credit facility with Citizens Bank providing up to $50 million of total availability, consisting of $30 million committed availability plus an accordion option of up to $20 million. The facility matures on January 2, 2029. As of closing, no amount was drawn and the company stated it expects existing cash and cash flow to fund organic growth. Interest is priced on a leverage-linked grid at either Term SOFR +150–225 bps or Alternate Base Rate +50–125 bps, with unused-commitment fees of 0.225%–0.30% and no upfront fee.
LifeMD (NASDAQ: LFMD) expanded its collaboration with Novo Nordisk to offer Wegovy pill (oral semaglutide) through LifeMD’s telehealth and integrated NovoCare Pharmacy services. The U.S. FDA approved the Wegovy pill on Dec 22, 2025 as the first oral GLP-1 for chronic weight management and certain cardiovascular risk reduction. A 64-week Phase 3 trial showed 16.6% mean weight loss versus 2.7% for placebo. Eligible patients can access Wegovy pills via LifeMD starting at $149/month, with staged price increases effective Apr 15, 2026. LifeMD offers virtual visits, nationwide testing, clinical oversight, and home delivery across all 50 states.
LifeMD (Nasdaq: LFMD) announced a cash dividend on its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) of $0.5546875 per share. The dividend is payable on January 15, 2026 to holders of record at the close of business on January 5, 2026. This declaration establishes the payment amount and the key record and payment dates for preferred shareholders.
LifeMD (Nasdaq: LFMD) announced on November 24, 2025 that it was recognized on the 2025 Deloitte Technology Fast 500 and on the inaugural TIME’s America’s Growth Leaders of 2026 list.
LifeMD said the honors reflect its continued revenue growth, financial stability, and expanding position in health technology driven by virtual primary care, pharmacy solutions, and growth in weight management, mental health, and hormone replacement therapy. Management highlighted investments in a differentiated enterprise platform, an affiliated compounding pharmacy, expanded insurance coverage, and strategic employer, pharma, and commercial partnerships.
LifeMD (Nasdaq: LFMD) reported Q3 2025 total revenue of $60.2M, up 13% year-over-year, and adjusted EBITDA of $5.1M, up 20%.
Telehealth revenue was $47.3M (+18%), telehealth adjusted EBITDA was $2.9M (+30%), and active telehealth subscribers were ~310,000 (+14%). The company paid off approximately $17M of debt and ended the quarter with $23.8M cash. Subsequent to quarter end, LifeMD divested its majority stake in WorkSimpli, positioning the company as a pure-play telehealth and pharmacy platform.
Guidance: Q4 2025 revenue $45M–$46M and adjusted EBITDA $3M–$4M; full-year 2025 revenue $192M–$193M (+~24%) and adjusted EBITDA $13.5M–$14.5M (+~254%).
LifeMD (Nasdaq: LFMD) announced a lower cash-pay price for GLP-1 medications Wegovy and Ozempic as part of its collaboration with Novo Nordisk. LifeMD will offer the 0.25 mg and 0.5 mg doses at $199 per month for two fills for new patients, which the company describes as the lowest cash-pay pricing nationwide.
The drugs are offered through the LifeMD Weight Management Program, which includes virtual consultations, diagnostic testing, secure messaging, and lifestyle education. LifeMD cited a strategic shift from compounded GLP-1s to direct manufacturer partnerships to align with regulatory and reimbursement trends and to scale virtual obesity and metabolic care.
LifeMD (Nasdaq: LFMD) will participate in the virtual BTIG Digital Health Forum on November 24, 2025. Management will join a virtual panel titled “Creating a Scalable Virtual Primary Care and Obesity Health Platform” at 4:00 p.m. Eastern time and will be available for one-on-one virtual meetings. Investors seeking to attend can register through their BTIG representative.